{"nctId":"NCT01889251","briefTitle":"A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion","startDateStruct":{"date":"2013-07"},"conditions":["Symptomatic Vitreomacular Adhesion"],"count":251,"armGroups":[{"label":"Ocriplasmin","type":"EXPERIMENTAL","interventionNames":["Drug: Ocriplasmin"]},{"label":"Sham injection","type":"SHAM_COMPARATOR","interventionNames":["Drug: Sham injection"]}],"interventions":[{"name":"Ocriplasmin","otherNames":["A01016"]},{"name":"Sham injection","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Symptomatic vitreomacular adhesion (VMA) which, in the opinion of the Investigator, is related to decreased visual function;\n* Best corrected visual acuity (BCVA) of 20/25 or worse in the study eye;\n* BCVA of 20/800 or better in the non-study eye;\n* Provide written informed consent;\n* Follow specified instructions during study period;\n* Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Evidence of proliferative retinopathy, exudative age-related macular degeneration, or retinal vein occlusion in the study eye;\n* Vitreous hemorrhage or other opacification;\n* High myopia in the study eye;\n* Ocular surgery, laser photocoagulation treatment, or intravitreal injection(s) in the study eye in the prior 3 months;\n* Uncontrolled glaucoma in the study eye;\n* History of retinal detachment in either eye;\n* Active infection in either eye;\n* Pregnant or of child-bearing potential and not utilizing acceptable form of contraception;\n* Participation in another investigational drug study within 30 days prior to this study;\n* Other protocol-defined exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Subjects With Non-Surgical Resolution of Vitreomacular Adhesion (VMA)","description":"VMA (adhesion of the vitreous gel to the retina in an abnormally strong manner) was determined by masked Central Reading Center (CRC) Spectral Domain Optical Coherence Tomography (SD-OCT) evaluation. Only one eye (study eye) was analyzed. Proportion of subjects is reported as a percentage.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.2","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":114},"commonTop":["Conjunctival haemorrhage","Vitreous floaters","Anterior chamber cell","Back pain","Eye pain"]}}}